Search results for: Certolizumab pegol

Beyond the Clinic: Lessons Learned from a Rheumatologist with RA

Linda Childers | November 7, 2023

A pediatric rheumatologist diagnosed with RA following the birth of her first child talks about integrative care & offers tips for helping patients reduce the symptom burden.

JAK Inhibitors vs. TNF Inhibitors: Understanding Infection Risks

Michele B. Kaufman, PharmD, BCGP | April 27, 2023

Research from Choi et al. provides insights into the risk of infection in patients with rheumatoid arthritis (RA), comparing patients treated with Janus kinase inhibitors vs. tumor necrosis inhibitors. The most frequent infection was herpes zoster, with patients treated with JAK inhibitors having a significantly greater risk of herpes zoster infection than those treated with TNF inhibitors.

Biologic or Conventional Therapy for Early RA?

Michele B. Kaufman, PharmD, BCGP | July 19, 2022

A study has shown that in untreated patients with early RA, treatment with methotrexate combined with the biologic therapies abatacept or certolizumab-pegol resulted in greater CDAI remission rates than active conventional therapy with prednisolone, sulfasalazine or hydroxychloroquine.

Medication Preferences & Current Practices for PsA

Michele B. Kaufman, PharmD, BCGP | May 11, 2022

With many new agents designed to treat PsA, rheumatologists and patients have options. Schwartzman et al. examined the real-world use of different treatments and ranked patient medication preferences.

The Ins & Outs of Patient Assistance Programs

Samantha C. Shapiro, MD | March 3, 2022

Although effective against rheumatic disease, biologic therapies come with hefty price tags. Patient assistance programs can be a useful resource to help under- and uninsured patients get the drugs they need.

Drug Transference in Pregnancy: RheumMadness 2022 TNFi in Cord Blood Scouting Report

University of Chicago Medicine: Lauren He, MD; & Cuoghi Edens, MD | March 2, 2022

A study was able to quantify the transference of tumor necrosis factor (TNF) inhibitors from mother to fetus during pregnancy. Overall, the researchers found low levels of transfer for the treatments studied.

Clinical Insights into Axial Spondyloarthritis: Rheumatology Drugs at a Glance, Part 5

Mary Choy, PharmD, BCGP, FASHP | February 10, 2022

Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options; others have few or only off-label options. This series, Rheumatology Drugs at a Glance, provides streamlined information on the administration of biologic, biosimilar and other medications used to…

TNF Inhibitors & Pregnancy: How Well Does the Treatment Guidance Work?

Michele B. Kaufman, PharmD, BCGP | October 21, 2021

Ghalandari et al. sought to validate the guidance outlined by EULAR for the use of anti-rheumatic drugs during pregnancy, finding that following its guidance for tumor necrosis factor inhibitors led to no or low concentrations of these agents in cord blood.

Psoriatic Arthritis Treatment Update

Mary Choy, PharmD, BCGP, FASHP | October 13, 2021

About 30% of patients with psoriasis have psoriatic arthritis (PsA), a complex, multi-faceted, chronic, inflammatory musculoskeletal and skin disease for which the treatment has changed considerably over the past few years.1 Biosimilars and other new drugs have become a therapeutic turning point for many patients suffering from rheumatic illnesses, including PsA. The treatment of PsA…

Vasculitis Guidelines in Focus, Part 5: Takayasu Arteritis

Michael Putman, MD | October 11, 2021

Andy Abril, MD, a lead author of the ACR/VF guideline for Takayasu arteritis (TAK), discusses the recommendations for TAK.